NuVasive and AlloSource have signed an agreement, under which AlloSource has licensed from NuVasive certain intellectual property related to bone growth products containing endogenous mesenchymal stem cells (MSCs).
The license and royalty agreement will enable AlloSource to distribute its recently-introduced allograft cellular product, AlloStem.
The agreement includes restrictions against AlloSource distributing into the spine market with a major partner other than NuVasive.
AlloSource currently processes Osteocel Plus for NuVasive.
NuVasive and AlloSource said in a joint statement that this license agreement strengthens the relationship between their organizations and further validates the strength of the allograft stem cell intellectual property held by NuVasive.
"Our partnership in the distribution of Osteocel Plus, which is processed by AlloSource for NuVasive, has been very positive. We are collectively excited about the research being conducted by our companies to advance tissue processing techniques and we look forward to our continued leadership in this market," the companies said.